 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| Chemical and physical data | |
| Formula | C25H29ClO6 |
| Molar mass | 460.95 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Janagliflozin is an SGLT2 inhibitor developed by Sihuan Pharmaceutical. [1] [2] [3] [4] [5] [6] It is approved in China for the treatment of type 2 diabetes. [7]
Drugs used in diabetes treat diabetes mellitus by decreasing glucose levels in the blood. With the exception of insulin, most GLP-1 receptor agonists, and pramlintide, all diabetes medications are administered orally and are thus called oral hypoglycemic agents or oral antihyperglycemic agents. There are different classes of hypoglycemic drugs, and selection of the appropriate agent depends on the nature of diabetes, age, and situation of the person, as well as other patient factors.
Sitagliptin, sold under the brand name Januvia among others, is an anti-diabetic medication used to treat type 2 diabetes. In the United Kingdom it is listed as less preferred than metformin or a sulfonylurea. It is taken by mouth. It is also available in the fixed-dose combination medication sitagliptin/metformin.
Romance of the Three Kingdoms is a Chinese television series adapted from the classical 14th century novel of the same title by Luo Guanzhong. The series was produced by China Central Television (CCTV) and was first aired on the network in 1994. It spanned a total of 84 episodes, each approximately 45 minutes long. One of the most expensive television series produced at the time, the project cost 170 million yuan. It was completed over four years and involved over 400,000 cast and crew members, including divisions of the People's Liberation Army from the Beijing, Nanjing and Chengdu military regions. Some of the dialogue spoken by characters was adapted directly from the novel. Extensive battle scenes, such as the battles of Guandu, Red Cliffs and Xiaoting, were also live-acted.
Dapagliflozin, sold under the brand names Farxiga (US) and Forxiga (EU) among others, is a medication used to treat type 2 diabetes. It is also used to treat adults with heart failure and chronic kidney disease. It reversibly inhibits sodium-glucose co-transporter 2 (SGLT2) in the renal proximal convoluted tubule to reduce glucose reabsorption and increase urinary glucose excretion.
Three Kingdoms is a 2010 Chinese television series based on the events in the late Eastern Han dynasty and the Three Kingdoms period. The plot is adapted from the 14th century historical novel Romance of the Three Kingdoms and other stories about the Three Kingdoms period. Directed by Gao Xixi, the series had a budget of over 160 million RMB and took five years of pre-production work. Shooting of the series commenced in October 2008, and it was released in China in May 2010.
Remogliflozin etabonate (INN/USAN) is a drug of the gliflozin class for the treatment of non-alcoholic steatohepatitis ("NASH") and type 2 diabetes. Remogliflozin was discovered by the Japanese company Kissei Pharmaceutical and is currently being developed by BHV Pharma, a wholly owned subsidiary of North Carolina, US-based Avolynt, and Glenmark Pharmaceuticals through a collaboration with BHV. In 2002, GlaxoSmithKline (GSK) received a license to use it. From 2002 to 2009, GSK carried out a significant clinical development program for the treatment of type-2 diabetes mellitus in various nations across the world and obesity in the UK. Remogliflozin etabonate's pharmacokinetics, pharmacodynamics, and clinical dose regimens were characterized in 18 Phase I and 2 Phase II investigations. Due to financial concerns, GSK stopped working on remogliflozin and sergliflozin, two further SGLT2 inhibitors that were licensed to the company, in 2009. Remogliflozin was commercially launched first in India by Glenmark in May 2019.
Gliflozins are a class of drugs in the treatment of type 2 diabetes (T2D). They act by inhibiting sodium/glucose cotransporter 2 (SGLT-2), and are therefore also called SGLT-2 inhibitors. The efficacy of the drug is dependent on renal excretion and prevents glucose from going into blood circulation by promoting glucosuria. The mechanism of action is insulin independent.
The Seven Heroes and Five Gallants is a 1994 Taiwanese television series produced by Chinese Television System (CTS) a few months after its prequel Justice Pao, which was also produced by Chao Ta-shen. Dozens of actors appeared in both series, but only Sze Yu and Tu Man-sheng reprised their roles. Fan Hung-hsuan and Lung Lung chose to portray new characters rather than their iconic roles.
SGLT2 inhibitors, also called gliflozins or flozins, are a class of medications that inhibit sodium-glucose transport proteins in the nephron, unlike SGLT1 inhibitors that perform a similar function in the intestinal mucosa. The foremost metabolic effect of this is to inhibit reabsorption of glucose in the kidney and therefore lower blood sugar. They act by inhibiting sodium-glucose transport protein 2 (SGLT2). SGLT2 inhibitors are used in the treatment of type 2 diabetes. Apart from blood sugar control, gliflozins have been shown to provide significant cardiovascular benefit in people with type 2 diabetes. As of 2014, several medications of this class had been approved or were under development. In studies on canagliflozin, a member of this class, the medication was found to enhance blood sugar control as well as reduce body weight and systolic and diastolic blood pressure.
The China women's national artistic gymnastics team represents China in FIG international competitions.
God of War, Zhao Yun, also known as Chinese Hero Zhao Zilong, released under the title Dynasty Warriors in Indonesia, is a 2016 Chinese television series directed by Cheng Lidong and produced by Zhejiang Yongle Entertainment Co., Ltd. The series starred cast members from mainland China, South Korea and Taiwan: Lin Gengxin, Im Yoon-ah and Kim Jeong-hoon. The story is loosely adapted from the 14th-century Chinese classical novel Romance of the Three Kingdoms, with Zhao Yun as the main character. It was first aired on Hunan TV from 3 April to 7 May 2016.
Gosogliptin is a drug for the treatment of type II diabetes. It is in the class of dipeptidyl peptidase-4 (DPP-4) inhibitors. It was discovered and developed through Phase 1 and Phase 2 by Pfizer. The crystal structure of DPP-4 in complex with gosogliptin is available. Its metabolism, excretion and pharmacokinetics in rat, dog and human have been described. A cost efficient route has been published. Other studies including Phase 3 studies were conducted in Russia. It is approved for use in Russia.
Bexagliflozin, sold under the brand name Brenzavvy, is an antidiabetic medication used to improve glycemic control in adults with type 2 diabetes. It is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that is taken by mouth.
Fotagliptin (SAL067) is a DPP-4 inhibitor under development for the treatment of type 2 diabetes. Like other DPP-4 inhibitors, it works by increasing endogenously produced GLP-1 and GIP. In a phase 3 trial it showed similar results as alogliptin.
Aficamten (CK-274) is a cardiac myosin inhibitor developed by Cytokinetics for the treatment of obstructive hypertrophic cardiomyopathy.
Cofrogliptin is a long-acting DPP4 inhibitor dosed once every two weeks.
Prusogliptin (DBPR108) is an experimental DPP-4 inhibitor developed by CSPC Pharmaceutical Group to treat type 2 diabetes.
Globalagliatin (SY-004) is a glucokinase activator developed by Yabao Pharmaceutical Group for type 2 diabetes.
Henagliflozin is a pharmaceutical drug for the treatment of type 2 diabetes. In China, it is approved for adult patients with type 2 diabetes to improve the glycemic control.